The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved therapies for non-small-cell lung cancer (NSCLC) harboring activating mutations in the EGFR kinase [1–3]. Here, EGFR is linked to non-small cell lung carcinoma.